Cannell & Spears’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$43.5M Sell
88,474
-656
-0.7% -$356K 0.85% 34
2025
Q4
$51.6M Buy
89,130
+24
+0% +$13.6K 0.97% 29
2025
Q3
$43.2M Sell
89,106
-2,300
-3% -$1.07M 0.82% 36
2025
Q2
$37.1M Sell
91,406
-2,067
-2% -$864K 0.75% 39
2025
Q1
$46.5M Sell
93,473
-777
-0.8% -$421K 1% 28
2024
Q4
$49M Sell
94,250
-15,637
-14% -$8.6M 1.01% 27
2024
Q3
$68M Sell
109,887
-759
-0.7% -$449K 1.34% 14
2024
Q2
$61.2M Sell
110,646
-4,891
-4% -$2.8M 1.27% 20
2024
Q1
$67.2M Buy
115,537
+7,453
+7% +$4.18M 1.39% 17
2023
Q4
$57.4M Buy
108,084
+382
+0.4% +$185K 4.57% 3
2023
Q3
$54.5M Sell
107,702
-145
-0.1% -$77.3K 4.67% 3
2023
Q2
$56.3M Buy
107,847
+222
+0.2% +$120K 4.59% 3
2023
Q1
$62M Sell
107,625
-84
-0.1% -$47.3K 5.55% 3
2022
Q4
$59.3M Sell
107,709
-4,061
-4% -$2.15M 5.66% 2
2022
Q3
$56.7M Sell
111,770
-2,511
-2% -$1.41M 5.6% 3
2022
Q2
$62.1M Buy
114,281
+383
+0.3% +$211K 5.6% 3
2022
Q1
$67.3M Sell
113,898
-13,842
-11% -$7.95M 4.99% 3
2021
Q4
$85.2M Sell
127,740
-651
-0.5% -$406K 5.75% 3
2021
Q3
$73.4M Sell
128,391
-474
-0.4% -$260K 5.3% 2
2021
Q2
$65M Sell
128,865
-373
-0.3% -$176K 4.67% 3
2021
Q1
$59M Sell
129,238
-14,644
-10% -$6.99M 4.56% 3
2020
Q4
$67M Sell
143,882
-998
-0.7% -$468K 5.6% 3
2020
Q3
$64M Sell
144,880
-495
-0.3% -$205K 6.09% 2
2020
Q2
$52.7M Sell
145,375
-41,048
-22% -$13.8M 5.54% 3
2020
Q1
$52.9M Buy
186,423
+12,953
+7% +$4.08M 6.47% 2
2019
Q4
$56.4M Sell
173,470
-339
-0.2% -$103K 6.03% 2
2019
Q3
$50.6M Sell
173,809
-4,962
-3% -$1.42M 5.87% 2
2019
Q2
$52.5M Buy
178,771
+34
+0% +$9.37K 6.17% 2
2019
Q1
$48.9M Sell
178,737
-596
-0.3% -$148K 6.24% 2
2018
Q4
$40.1M Sell
179,333
-4,021
-2% -$943K 5.89% 2
2018
Q3
$44.8M Sell
183,354
-3,357
-2% -$772K 5.35% 2
2018
Q2
$38.7M Sell
186,711
-985
-0.5% -$209K 5.02% 2
2018
Q1
$38.8M Sell
187,696
-1,720
-0.9% -$361K 5.04% 2
2017
Q4
$36M Buy
189,416
+4,260
+2% +$816K 4.38% 5
2017
Q3
$35M Sell
185,156
-2,206
-1% -$400K 4.19% 6
2017
Q2
$32.7M Sell
187,362
-11,566
-6% -$1.94M 4.06% 9
2017
Q1
$30.6M Sell
198,928
-63,701
-24% -$9.74M 3.86% 9
2016
Q4
$37.1M Sell
262,629
-16,615
-6% -$2.45M 4.76% 4
2016
Q3
$44.4M Sell
279,244
-17,490
-6% -$2.7M 5.59% 2
2016
Q2
$43.8M Sell
296,734
-41,089
-12% -$6.06M 5.56% 2
2016
Q1
$47.8M Sell
337,823
-2,022
-0.6% -$271K 5.84% 2
2015
Q4
$48.2M Sell
339,845
-2,058
-0.6% -$274K 5.52% 1
2015
Q3
$41.8M Buy
341,903
+4,998
+1% +$651K 4.78% 2
2015
Q2
$43.7M Buy
336,905
+332
+0.1% +$43.3K 4.84% 4
2015
Q1
$45.2M Sell
336,573
-160
-0% -$20.6K 5.41% 1
2014
Q4
$42.2M Buy
336,733
+42,723
+15% +$5.19M 4.68% 2
2014
Q3
$35.8M Sell
294,010
-2,355
-0.8% -$286K 4.28% 4
2014
Q2
$35M Buy
296,365
+2,783
+0.9% +$328K 4.13% 6
2014
Q1
$35.3M Sell
293,582
-74,875
-20% -$8.9M 4.44% 2
2013
Q4
$41M Sell
368,457
-8,745
-2% -$870K 5.12% 1
2013
Q3
$34.8M Sell
377,202
-1,355
-0.4% -$123K 4.53% 3
2013
Q2
$32M Buy
+378,557
New +$31.5M 4.72% 3

Other funds holding TMO

Cannell & Spears's TMO Position: Q1 2026 in Review

Cannell & Spears reduced its Thermo Fisher Scientific (TMO) stake by 0.74% in Q1 2026, selling an estimated $356K and leaving 88,474 shares worth $43.5M. The position accounts for 0.85% of the portfolio, ranked #34.

Cannell & Spears first reported a position in TMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $85.2M in Q4 2021. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Cannell & Spears held 88,474 shares of Thermo Fisher Scientific worth $43.5M as of Q1 2026.
  • Cannell & Spears sold 656 Thermo Fisher Scientific shares in Q1 2026, an estimated $356K.
  • Thermo Fisher Scientific made up 0.85% of Cannell & Spears's portfolio in Q1 2026, its #34 holding.
  • Cannell & Spears first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 52 quarters since.
  • Cannell & Spears's Thermo Fisher Scientific position peaked at $85.2M in Q4 2021.
  • 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Cannell & Spears's 13F filing for Q1 2026, filed 14 May 2026.